¤é´Á |
¿³ÂdªÑ²¼¤½¥q¦WºÙ |
·s»D¼ÐÃD |
2022/10/25 | ¨ÈªG¹C¸¥ ¿³ | ¤½§i¥»¤½¥q¸³¨Æ·|¸Ñ°£¸g²z¤HÄv·~¸T¤î¤§¨î |
1.¸³¨Æ·|¨Mij¤é´Á:111/10/252.³\¥i±q¨ÆÄv·~¦æ¬°¤§¸g²z¤H©m¦W¤Î¾ºÙ:(1)±i¼y²»/Á`¸g²z(2)ð¥É®Ñ/Á`¸g²z3.³\¥i±q¨ÆÄv·~¦æ¬°¤§¶µ¥Ø:(1)±i¼y²»/¨È¥¶}µoªÑ¥÷¦³¤½¥q¸³¨Æªø(2)ð¥É®Ñ/®ÙÖö¦³¤½¥q¸³¨Æªø4.³\¥i±q¨ÆÄv·~¦æ¬°¤§´Á¶¡:¥ô¾¥»¤½¥q¸g²z¤H´Á¶¡5.¨Mij±¡§Î¡]½Ð¨Ì¤½¥qªk²Ä32±ø»¡©úªí¨Mµ²ªG¡^:¸g¼x¸ß¥þÅé¥X®u¸³¨Æ¦P·N·Ó®×³q¹L6.©Ò³\¥i¤§Äv·~¦æ¬°¦pÄݤj³°¦a°Ï¨Æ·~¤§Àç·~ªÌ¡A¸g²z¤H©m¦W¤Î¾ºÙ¡]«DÄݤj³°¦a°Ï¨Æ·~¤§Àç·~ªÌ¡A¥H¤UÄæ¦ì½Ð¿é¤£¾A¥Î¡^:¤£¾A¥Î7.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¤§¤½¥q¦WºÙ¤Î¾°È:¤£¾A¥Î8.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~¦a§}:¤£¾A¥Î9.©Ò¾á¥ô¸Ó¤j³°¦a°Ï¨Æ·~Àç·~¶µ¥Ø:¤£¾A¥Î10.¹ï¥»¤½¥q°]°È·~°È¤§¼vÅTµ{«×:¤£¾A¥Î11.¸g²z¤H¦p¦³¹ï¸Ó¤j³°¦a°Ï¨Æ·~±q¨Æ§ë¸êªÌ¡A¨ä§ë¸êª÷ÃB¤Î«ùªÑ¤ñ¨Ò:¤£¾A¥Î12.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ¨ÈªG¹C¸¥ ¿³ | ¤½§i¥»¤½¥qµo¨¥¤H²§°Ê |
1.¤HûÅܰʧO¡]½Ð¿é¤Jµo¨¥¤H¡B¥N²zµo¨¥¤H¡B«nÀç¹B¥DºÞ(¦p:°õ¦æªø¡BÀç¹Bªø¡B¦æ¾Pªø¤Îµ¦²¤ªøµ¥)¡B¶D³^¤Î«D¶D³^¥N²z¤H¡B°]°È¥DºÞ¡B·|p¥DºÞ¡B¤½¥qªv²z¥DºÞ¡B¸ê°T¦w¥þªø¡B¬ãµo¥DºÞ©Î¤º³¡½]®Ö¥DºÞ¡^:µo¨¥¤H2.µo¥ÍÅܰʤé´Á:111/10/253.ÂÂ¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:±i¼y²»/¥»¤½¥qì¥ôÁ`¸g²z/¨ÈªG¹C¸¥¶}µoªÑ¥÷¦³¤½¥qÁ`¸g²z4.·s¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:ð¥É®Ñ/¥»¤½¥q·s¥ôÁ`¸g²z/ªá½¬¿¤¬F©²Æ[¥ú³B³Bªø5.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¾°È½Õ¾ã¡v¡B¡u¸ê»º¡v¡B¡u°h¥ð¡v¡B¡u¦º¤`¡v¡B¡u·s¥ô¡v©Î¡u¸Ñ¥ô¡v¡^:¾°È½Õ¾ã6.²§°Êì¦]:¾°È½Õ¾ã7.¥Í®Ä¤é´Á:111/11/018.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ¨ÈªG¹C¸¥ ¿³ | ¤½§i¥»¤½¥qÁ`¸g²z²§°Ê |
1.¸³¨Æ·|¨Mij¤é´Á©Îµo¥ÍÅܰʤé´Á:111/10/252.¤Hû§O¡]½Ð¿é¤J¸³¨Æªø©ÎÁ`¸g²z¡^:Á`¸g²z3.ÂÂ¥ôªÌ©m¦W:±i¼y²»4.ÂÂ¥ôªÌ²¾ú:¥»¤½¥qÁ`¸g²z5.·s¥ôªÌ©m¦W:ð¥É®Ñ6.·s¥ôªÌ²¾ú:ªá½¬¿¤¬F©²Æ[¥ú³B³Bªø7.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¸Ñ¥ô¡v¡B¡u¥ô´Á©¡º¡¡v¡B¡u¾°È½Õ¾ã¡v¡B¡u¸ê»º¡v¡B¡u°h¥ð¡v¡B¡u³u¥@¡v©Î¡u·s¥ô¡v¡^:¾°È½Õ¾ã8.²§°Êì¦]:¾°È½Õ¾ã9.·s¥ô¥Í®Ä¤é´Á:111/11/0110.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | »E«í¬ì§Þ ¿³ | ¤½§i111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§¬y°Ê¤ñ²v¡B³t°Ê¤ñ²v ¤Ît |
¤½§i111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§¬y°Ê¤ñ²v¡B³t°Ê¤ñ²v ¤Ît¶Å¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/252.µo¥Í½t¥Ñ:¨ÌÂd¶R¤¤¤ßÃÒÂd¼f¦r²Ä1110101557¸¹¨çn¨D¿ì²z¤½§i¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111/094.¦Ûµ²¬y°Ê¤ñ²v:181.63%5.¦Ûµ²³t°Ê¤ñ²v:83.74%6.¦Ûµ²t¶Å¤ñ²v:73.44%7.¦]À³±¹¬I:¨C¤ë©³«e¤½§i¦Ûµ²¦X¨Ö°]°È³ø§iºI¦Ü«e¤@¤ë©³¤§¬y°Ê¤ñ²v¡B³t°Ê¤ñ²v¤Ît¶Å¤ñ²v¡C8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | »ÍÄ_¤u·~ ¿³ | ¤½§i¥»¤½¥q111¦~09¤ë¥÷¦Ûµ²°]°È³ø§i¤§¬y°Ê¤ñ²v¡B ³t°Ê¤ñ²v |
¤½§i¥»¤½¥q111¦~09¤ë¥÷¦Ûµ²°]°È³ø§i¤§¬y°Ê¤ñ²v¡B ³t°Ê¤ñ²v¤Ît¶Å¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/252.µo¥Í½t¥Ñ:¦]¥»¤½¥q108¦~«×²Ä¤G©u°]°È³ø§i¤§t¶Å¤ñ²v°¾°ª¹F64.63%¡A ¨ÌÂd¶R¤¤¤ßÃÒÂd¼f¦r²ÄÃÒÂd¼f¦r²Ä1080100983¸¹¨çn¨D¿ì²z¤½§i¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111/094.¦Ûµ²¬y°Ê¤ñ²v:118.79%5.¦Ûµ²³t°Ê¤ñ²v:54.78%6.¦Ûµ²t¶Å¤ñ²v:63.09%7.¦]À³±¹¬I:¨C¤ë©³«e¤½§i¦Ûµ²°]°È³ø§iºI¦Ü«e¤@¤ë©³¤§¬y°Ê¤ñ²v¡B ³t°Ê¤ñ²v¤Ît¶Å¤ñ²v¡C8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ®õ³Ð¤uµ{ ¿³ | ¤½§i¥»¤½¥q111¦~09¤ë¥÷¦Ûµ²°]°È³øªí¤§°]°È¤ñ²v |
1.¨Æ¹êµo¥Í¤é:111/10/252.µo¥Í½t¥Ñ:¨Ì°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß109¦~5¤ë13¤éÃÒÂd¼f¦r²Ä¡@1090100525¸¹¨ç¿ì²z¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111/094.¦Ûµ²¬y°Ê¤ñ²v:116.31%5.¦Ûµ²³t°Ê¤ñ²v:54.85%6.¦Ûµ²t¶Å¤ñ²v:80.31%7.¦]À³±¹¬I:µL8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | º~¹F¥Í§Þ ¿³ | ¤½§i¥»¤½¥q¦³Ãö¬ü°ê±M§Q«IÅv¶D³^®×¹F¦¨©M¸Ñ¬ÛÃö ¨Æ©y(¶D³^²×µ² |
¤½§i¥»¤½¥q¦³Ãö¬ü°ê±M§Q«IÅv¶D³^®×¹F¦¨©M¸Ñ¬ÛÃö ¨Æ©y(¶D³^²×µ²) 1.ªk«ß¨Æ¥ó¤§·í¨Æ¤H: ì§i¡GNovartis Pharmaceuticals Corporation ³Q§i¡GHanda Neuroscience, LLC¡BHanda Pharmaceuticals, Inc. Handa Pharma,Inc.¡BHanda Pharmaceuticals, LLC2.ªk«ß¨Æ¥ó¤§ªk°|¦WºÙ©Î³B¤À¾÷Ãö: District of Delaware (Wilmington) of U.S. District Court3.ªk«ß¨Æ¥ó¤§¬ÛÃö¤å®Ñ®×¸¹:1:21-cv-00645-UNA4.¨Æ¹êµo¥Í¤é:111/10/255.µo¥Íì©e¡]§tª§³^¼Ðªº¡^: Novartis Pharmaceuticals Corporation(¥H¤U²ºÙNovartis)©ó¬ü°ê®É¶¡2021¦~5¤ë4¤é ¹ïº~¹F¤Îº~¹F¬ü°ê¤l¤½¥q´£¥XTASCENSO ODT(§YHND-020), 0.5²@§J±M§Q«IÅv¶D³^¡C6.³B²z¹Lµ{: ¥»¤½¥q©ó¬ü°ê®É¶¡2022¦~10¤ë24¤éñq©M¸Ñ¨óij®Ñ¡ANovartis±N¨Ì¨óijºM¦^©Ò¦³¬ÛÃö¶D ³^¨Ã²×µ²¥»®×¡CÂù¤è´N¥»®×¤§¤@¤Á¬ÛÃöijÃD¡A¥ç¤£±o¦A¦V¥L¤è¶i¦æ¥ô¦ó°l¯Á¤Î¥D±i¡C7.¹ï¤½¥q°]°È·~°È¼vÅT¤Î¹w¦ô¼vÅTª÷ÃB: TASCENSO ODT©ó¬ü°ê¥«³õ¤W¥«¾P°â«á¡A¨Ì¾Ú©M¸Ñ¨óij¡A©ó¯S©w±ø¥ó¤Uº~¹F±N¨Ì¾P°â²bÃB ¤§¤@©w¤ñ¨Ò¤ä¥INovartisÅv§Qª÷¡F©M¸Ñ¨óij¤§²Ó¸`¡A°ò©ó«O±K±ø´Ú¤§¨î¡AÂù¤è§¡¤£±o ´¦ÅS¡C8.¦]À³±¹¬I¤Î§ïµ½±¡§Î:¥»¤½¥q±N¨Ì©M¸Ñ¨óij¹ð¦æ¬ÛÃöÅv§Q¤Î¸q°È¡C9.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)TASCENSO ODT, 0.5²@§J¤w©ó¬ü°ê®É¶¡2021¦~10¤ë18¤é¨ú±oFDA¼È®É³\¥i(Tentative Approval)¡A¦]º~¹F¤w»PNovartisñq©M¸Ñ¨óij(¶D³^²×µ²)¡Aº~¹F±N¦VFDA¥Ó½Ð´«¦¨ ¡u³Ì²×®Öã (Final Approval)¡v¡A¨Ã¾¨³t±NTASCENSO ODT²£«~©ó¬ü°ê¥«³õ¤W¥«¡C (2)¦¹Ãþ±M§Q¶D³^«Y¬ü°êÃÄÃҥӽФ¤±M§Q¬D¾Ôªº¨Ò¦æ©Êµ{§Ç¡A±`¥X²{¦b505(b)(2)·sÃĶ} µo¹Lµ{¡A¬°²£·~Ävª§±`ºA¡C¶D³^µ¦²¤»P°Ó·~µ¦²¤¦³Ãö¡A¦]¦¹¥»¤½¥q»PNovartisñq ©M¸Ñ¨óij«Y¬°¥[³tTASCENSO ODTÃÄ«~§Ö³t¶i¤J¥«³õ¡A¥H§K°£¾Ç¦WÃĪºª½±µÄvª§¡A©µ ªø²£«~¥Í©R¶g´Á¡A½T«O²£«~¦¬¯q¡C (3)¦¹©M¸Ñ¨óij¹ï¥»¤½¥q»PCycle Pharmaceuticals Ltd.¤wñq¤§TASCENSO ODT¬ü°ê¥«¡@ ³õ¿W®a¾P°â±ÂÅv¦X¬ù¦³¥¿¦V¼vÅT¡A°Ó·~¶q²£ªº·Ç³Æ¤w«ùÄò¿n·¥¶i¦æ¤¤¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ¤[¸Î¿³·~ ¿³ | ¤½§i¥»¤½¥q111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê ¤ñ |
¤½§i¥»¤½¥q111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê ¤ñ²v¤Î³t°Ê¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/252.µo¥Í½t¥Ñ:¦]¥»¤½¥q103¦~«×°]°È³ø§i¤§t¶Å¤ñ²v°¾°ª¹F73.18%¡A¨ÌÂd¶R¤¤¤ßÃÒÂd¼f¦r²Ä1040100811¸¹¨çn¨D¿ì²z¤½§i¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111/094.¦Ûµ²¬y°Ê¤ñ²v:107.58%5.¦Ûµ²³t°Ê¤ñ²v:69.40%6.¦Ûµ²t¶Å¤ñ²v:63.40%7.¦]À³±¹¬I:¨C¤ë©³«e¤½§i¦Ûµ²°]°È³ø§iºI¦Ü«e¤@¤ë©³¤§¬y°Ê¤ñ²v¡B³t°Ê¤ñ²v¤Ît¶Å¤ñ²v¡C8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ¸ô©ö²ï¾ ¿³ | ¤½§i¥»¤½¥q111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§¬y°Ê¤ñ²v¡B ³t°Ê¤ñ |
¤½§i¥»¤½¥q111¦~9¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§¬y°Ê¤ñ²v¡B ³t°Ê¤ñ²v¤Ît¶Å¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/252.µo¥Í½t¥Ñ:¨Ì¾Ú¡u°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¡vÃÒÂd¼f¦r²Ä1110100835¸¹¨ç¿ì²z¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111¦~9¤ë4.¦Ûµ²¬y°Ê¤ñ²v:94.54%5.¦Ûµ²³t°Ê¤ñ²v:82.17%6.¦Ûµ²t¶Å¤ñ²v:75.27%7.¦]À³±¹¬I:¨C¤ë©³«e¤½§iºI¦Ü«e¤@¤ë©³¦Ûµ²¦X¨Ö°]°È³ø§i¤§¬y°Ê¤ñ²v¡B³t°Ê¤ñ²v¤Ît¶Å¤ñ²v¡C8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ºa¬´¬ì§Þ ¿³ | §ó¥¿111/5/24¤½§i¥»¤½¥q¸êª÷¶U»P¤l¤½¥q(«O¤sºa¾Y)¨Æ©y |
1.¨Æ¹êµo¥Í¤é:111/01/172.±µ¨ü¸êª÷¶U»P¤§:(1)¤½¥q¦WºÙ:«O¤sºa¾Y¬ì§Þ¦³¤½¥q(2)»P¸êª÷¶U»P¥L¤H¤½¥q¤§Ãö«Y:100%Âà§ë¸ê¤§¤l¤½¥q(3)¸êª÷¶U»P¤§ÃB(¥a¤¸):587,070(4)ì¸êª÷¶U»P¤§¾lÃB(¥a¤¸):43,430(5)¥»¦¸·s¼W¸êª÷¶U»P¤§ª÷ÃB(¥a¤¸):65,145(6)¬O§_¬°¸³¨Æ·|±ÂÅv¸³¨Æªø¹ï¦P¤@¶U»P¹ï¶H¤À¦¸¼·¶U©Î´`Àô°Ê¥Î¤§¸êª÷¶U»P:¬O(7)¨´¨Æ¹êµo¥Í¤é¤î¸êª÷¶U»P¾lÃB(¥a¤¸):108,575(8)¥»¦¸·s¼W¸êª÷¶U»P¤§ì¦]:µu´Á¿Ä³q3.±µ¨ü¸êª÷¶U»P¤½¥q©Ò´£¨Ñ¾á«O«~¤§:(1)¤º®e:µL(2)»ùÈ(¥a¤¸):04.±µ¨ü¸êª÷¶U»P¤½¥q³Ìªñ´Á°]°È³øªí¤§:(1)¸ê¥»(¥a¤¸):604,758(2)²Ö¿n¬ÕÁ«ª÷ÃB(¥a¤¸):-9,7245.p®§¤è¦¡:¦~§Q²v2%6.ÁÙ´Ú¤§:(1)±ø¥ó:¦Û©ñ´Ú¤é°_ºâ¡A´Á¶¡¬°´Á¤@¦~¡A¨ì´Á¤@¦¸ÀvÁÙ(2)¤é´Á:¦Û©ñ´Ú¤é°_ºâ¡A´Á¶¡¬°´Á¤@¦~7.¨´¨Æ¹êµo¥Í¤é¬°¤î¡A¸êª÷¶U»P¾lÃB(¥a¤¸):538,5328.¨´¨Æ¹êµo¥Í¤é¬°¤î¡A¸êª÷¶U»P¾lÃB¥e¤½¶}µo¦æ¤½¥q³Ìªñ´Á°]°È³øªí²bȤ§¤ñ²v:18.649.¤½¥q¶U»P¥L¤H¸êª÷¤§¨Ó·½:¤l¤½¥q¥»¨¡B¥À¤½¥q10.¨ä¥LÀ³±Ô©ú¨Æ¶µ:§ó¥¿111/5/24¤½§i(×¥¿1/17¸êª÷¶U»Pª÷ÃB¹F³B²z·Ç«h²Ä¤G¤Q¤G±ø²Ä¤@¶µ²Ä¤T´Ú¤½§i)<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ºa¬´¬ì§Þ ¿³ | §ó¥¿111/4/25¤½§i¥»¤½¥q¸êª÷¶U»P¤l¤½¥q(«O¤sºa¾Y)¨Æ©y |
1.¨Æ¹êµo¥Í¤é:111/04/252.±µ¨ü¸êª÷¶U»P¤§:(1)¤½¥q¦WºÙ:«O¤sºa¾Y¬ì§Þ¦³¤½¥q(2)»P¸êª÷¶U»P¥L¤H¤½¥q¤§Ãö«Y:100%Âà§ë¸ê¤§¤l¤½¥q(3)¸êª÷¶U»P¤§ÃB(¥a¤¸):577,793(4)ì¸êª÷¶U»P¤§¾lÃB(¥a¤¸):112,650(5)¥»¦¸·s¼W¸êª÷¶U»P¤§ª÷ÃB(¥a¤¸):76,602(6)¬O§_¬°¸³¨Æ·|±ÂÅv¸³¨Æªø¹ï¦P¤@¶U»P¹ï¶H¤À¦¸¼·¶U©Î´`Àô°Ê¥Î¤§¸êª÷¶U»P:¬O(7)¨´¨Æ¹êµo¥Í¤é¤î¸êª÷¶U»P¾lÃB(¥a¤¸):189,252(8)¥»¦¸·s¼W¸êª÷¶U»P¤§ì¦]:µu´Á¿Ä³q3.±µ¨ü¸êª÷¶U»P¤½¥q©Ò´£¨Ñ¾á«O«~¤§:(1)¤º®e:µL(2)»ùÈ(¥a¤¸):04.±µ¨ü¸êª÷¶U»P¤½¥q³Ìªñ´Á°]°È³øªí¤§:(1)¸ê¥»(¥a¤¸):604,758(2)²Ö¿n¬ÕÁ«ª÷ÃB(¥a¤¸):-62,9415.p®§¤è¦¡:¦~§Q²v2%6.ÁÙ´Ú¤§:(1)±ø¥ó:¦Û©ñ´Ú¤é°_ºâ¡A´Á¶¡¬°´Á¤@¦~¡A¨ì´Á¤@¦¸ÀvÁÙ(2)¤é´Á:¦Û©ñ´Ú¤é°_ºâ¡A´Á¶¡¬°´Á¤@¦~7.¨´¨Æ¹êµo¥Í¤é¬°¤î¡A¸êª÷¶U»P¾lÃB(¥a¤¸):702,9368.¨´¨Æ¹êµo¥Í¤é¬°¤î¡A¸êª÷¶U»P¾lÃB¥e¤½¶}µo¦æ¤½¥q³Ìªñ´Á°]°È³øªí²bȤ§¤ñ²v:24.339.¤½¥q¶U»P¥L¤H¸êª÷¤§¨Ó·½:¤l¤½¥q¥»¨¡B¥À¤½¥q10.¨ä¥LÀ³±Ô©ú¨Æ¶µ:§ó¥¿111/4/25¤½§i¥»¤½¥q¸êª÷¶U»P¤l¤½¥q(«O¤sºa¾Y)¨Æ©y<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | ¤¯·sÂåÃÄ ¿³ | ¼á²M´CÅé³ø¾É |
1.¶Ç¼½´CÅé¦WºÙ:¤u°Ó®É³ø²ÄB04ª©/¸gÀÙ¤é³ø²ÄC04ª©2.³ø¾É¤é´Á:111/10/253.³ø¾É¤º®e:(1)¤u°Ó®É³ø:¡u¡KLBS-008¥Î©óªvÀø´µ¯S®æ¯fÅÜ¡]STGD1¡^¡A¹wp©ú¦~²Ä¤G©u§¹¦¨¤T´ÁÁ{§É¸ÕÅ禬®×¡A³Ì§Ö2024¦~´Á¤¤¤ÀªR¡A¦³¾÷·|¦¨¬°¥þ²yº´ÚªvÀø¸Ó²´¯eªº¤fªAÃĪ«¡F¦Óªv°®©Ê¶À´³³¡¯fÅܤ]¹wp¤µ¦~²Ä¥|©u«×±Ò°Ê¤G¡þ¤T´Á¸ÕÅç¡A¹wp¤G¦~¤º§¹¦¨¦¬®×¡C¡v¡u¡KLBS-008¬O¥þ²y°ß¤@ªºSTGD1²Ä¤T´ÁÁ{§É¸ÕÅç¡A¥Ø¼Ð©ú¦~²Ä¤G©u§¹¦¨¤T´ÁÁ{§É¸ÕÅç¡A¹wp¦¬®×60¤H¡AÆ[¹î´Á¤G¦~¡A¹wp2025¦~§¹¦¨¡A¦pªG2024¦~´Á¤¤¤ÀªR¼Æ¾Ú¥¿¦V¡A¤£±Æ°£´£«e¥Ó½Ð¤W¥«¡C¡v¡u¡K¤¯·s±N¹B¥ÎºX¤UCDC7§Þ³N¥¥x¶}µo¥XLBS-007¡A°£¤F±N¦b¿D¬w¶i¦æ«æ©Ê¥Õ¦å¯fÁ{§É¥~¡A¤w³W¹º©ú¦~¦b¥xÆWªì°e¥ó¥Ó½ÐIND¡A«áÄò¥i¯à¦b¨È¤Ó§ä²Ä¤TÓ°ê®a¶i¦æ¦¬®×¡A¹wp¤G¡ã¤T¦~§¹¦¨¦¬®×¡C¡v(2)¸gÀÙ¤é³ø:¡u¡KLBS-008À³¥Î¦b´µ¯S®æ¯fÅÜ¡B¤Î°®©Ê¶À¯Z³¡¯fÅܨⶵ²´¬ì·sÃij£¦³¶i®i¡A¨ä¤¤°w¹ï´µ¯S®æ¯fÅܪº¤T´ÁÁ{§É¹wp©ú¦~3¡B4¤ë¦¬®×¡A¤§«áª§¨ú¨â¦~¤º¨ú±oÃÄÃÒ¡F°®©Ê¶À¯Z³¡¯fÅܪº¤T´ÁÁ{§É¸ÕÅç³Ì§Ö¦~©³±N´£¥X¥Ó½Ð¡A¥Ø¼Ð·m§ð¥þ²y200»õ¬ü¤¸¥«³õ°Ó¾÷¡C¡v¡u¡K¤¯·sªºLBS-008¤wµo®i¥X´µ¯S®æ¯fÅÜ¡B¤Î°®©Ê¶À¯Z³¡¯fÅܨⶵ¾AÀ³¯g·sÃÄ¡A¨ä¤¤´µ¯S®æ¯fÅܪº60¤H¤T´ÁÁ{§É¸ÕÅç¹wp©ú¦~3¡B4¤ë§¹¦¨¦¬®×¡A±µµÛ¶i¦æ¨â¦~ªºÆ[¹î´Á¡A¦pªG2024¦~´Á¤¤¤ÀªR¼Æ¾Ú¥¿¦V¡A¤£±Æ°£´£«e¥Ó½Ð¤W¥«¡C¡v¡u¤¯·sLBS-008°w¹ï°®©Ê¶À¯Z³¡¯fÅܪº¾AÀ³¯g¡A¤]¹wp¤µ¦~©³©Î©ú¦~ªì¥Ó½Ð¤T´ÁÁ{§É¸ÕÅç¡A¾ãÓ¸ÕÅç³]p¦Ü¤Ö¼Æ¦Ê¤H¡A³W¹º¨â¦~®É¶¡§¹¦¨¤T´ÁÁ{§É¡v4.§ë¸ê¤H´£¨Ñ°T®§·§n:¤£¾A¥Î5.¤½¥q¹ï¸Óµ¥³ø¾É©Î´£¨Ñ°T®§¤§»¡©ú:¤Wz³ø¾É¯ÂÄÝ´CÅéÁr´ú±À¦ô¡A¬ÛÃö°T®§À³¥H¥»¤½¥q¤½§G©ó¤½¶}¸ê°TÆ[´ú¯¸¤§¤½§i¸ê°T¬°·Ç¡A¯S¦¹¼á²M¡C6.¦]À³±¹¬I:µo§G«¤j°T®§»¡©ú¡C7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/25 | µØ¼w°Ê¯à ¿³ | ¥»¤½¥q»P¨®¤ý¹q¤lªÑ¥÷¦³¤½¥qÁp¦X½u¤Wªk¤H»¡©ú·| |
²Å¦X±ø´Ú²ÄXX´Ú¡G30¨Æ¹êµo¥Í¤é¡G111/10/251.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G111/10/252.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G14 ®É 30 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G½u¤Wªk»¡·|4.ªk¤H»¡©ú·|¾Ün°T®§¡G¸s¯qª÷¹©ÃÒ¨é¥D¿ì¥»¤½¥q»P¨®¤ý¹q¤lªÑ¥÷¦³¤½¥qÁp¦Xªk¤H»¡©ú·|¡A»¡©ú¥»¤½¥qÀç¹B·§ªp¤Î®i±æ¡C5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡G¦³¡Aºô§}¡G www.racev.com7.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡G§¹¾ã°]°È·~°È¸ê°T½Ð¦Ü¤½¶}¸ê°TÆ[´ú¯¸¤§ªk¤H»¡©ú·|¤@Äýªí©Îªk»¡·|¶µ¥Ø¤U¬d¾\¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | §»ùÖ¹CÀ¸ ¿³ | ¤½§i¥»¤½¥q¨Mij¦Vª÷¿ÄºÊ·þºÞ²z©eû·|¥Ó½Ð½Õ¾ã111¦~²{ª÷ ¼W¸ê |
¤½§i¥»¤½¥q¨Mij¦Vª÷¿ÄºÊ·þºÞ²z©eû·|¥Ó½Ð½Õ¾ã111¦~²{ª÷ ¼W¸ê®×µo¦æ»ù®æ 1.¨Æ¹êµo¥Í¤é:111/10/242.¤½¥q¦WºÙ:§»ùÖ¹CÀ¸ªÑ¥÷¦³¤½¥q3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î5.µo¥Í½t¥Ñ:(1)¥»¤½¥q©ó111¦~9¤ë27¤é¸³¨Æ·|¨Mij¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ10,000,000ªÑ¡A¨C ªÑ±ÃB·s¥x¹ô¡]¤U¦P¡^10¤¸¾ã¡A¨äÅv§Q¸q°È»P¤wµo¦æ´¶³qªÑ¬Û¦P¡C¥»¦¸²{ª÷¼W ¸êµo¦æ»ù®æ¼Èq¬°¨CªÑ80¤¸¾ã¡A¹wp¦@¥i¶Ò¶°800,000,000¤¸¾ã¡A±©¹ê»Úµo¦æ »ù®æ¸³¨Æ·|±ÂÅv¸³¨Æªø°Ñ°u·í®É¥«³õª¬ªp¤Î¨Ì¬ÛÃöÃÒ¨éªk¥O¡A©ó¨CªÑ·s»O¹ô73 ¦Ü81¤¸¤§¶¡q©w¤§¡A¥H¤W·~¤w©ó¦P¤éµo¥¬«¤j°T®§¤½§i¦b®×¡C(2)¯÷¦]ªñ´Á°ê»Ú¬F¸g±¡¶ÕÅܤƤΥxÆW¾ãÅéÃÒ¨é¥æ©ö¥«³õ»ù®æ¨ü¨ì¥þ²yÀô¹Ò¼vÅT¡A ¸³¨Æªø¨Ì¸³¨Æ·|¤§±ÂÅv¡A°Ñ°u·í«e¥«³õª¬ªp¡A¨Ã¨Ì¬ÛÃöÃÒ¨éªk¥O¡A½Õ¾ã¥»¦¸²{ ª÷¼W¸êµo¦æ»ù®æ¬°·s¥x¹ô73¤¸¡C¥»¤½¥q±N¦Vª÷¿ÄºÊ·þºÞ²z©eû·|ÃÒ¨é´Á³f§½¥Ó ½Ð½Õ¾ã¡C(3)¥»¤½¥q¼W¸êpµe¸êª÷¥Î³~¤Îµo¦æªÑ¼Æ¬Òºû«ù¤£ÅÜ¡C6.¦]À³±¹¬I:µL7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¥»¤½¥q¤w¨Ìªk¥O¤½§i¤§»{ªÑ°ò·Ç¤é¡BìªÑªF¤Îû¤uú´Ú´Á¶¡¡B¼W¸ê°ò·Ç¤éµ¥¸ê°T¡A±©©|¥¼±Hµoú´Ú³qª¾®Ñ¤©ìªÑªF¤Îû¤u¡C¬ÛÃö®Éµ{¦p»ÝÅÜ°Ê¡A¥»¤½¥q±N«S¥DºÞ¾÷Ãö®Öã«á¥t¦æ¤½§i¤§¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | µú³Ó©÷ ¿³ | ¤½§i¥»¤½¥qt³d¤H¶D³^®×®×¥ó¶i«× |
1.ªk«ß¨Æ¥ó¤§·í¨Æ¤H:¸³¨Æªø§d®ÑªN2.ªk«ß¨Æ¥ó¤§ªk°|¦WºÙ©Î³B¤À¾÷Ãö:»OÆW°ªµ¥ªk°| »O«n¤À°|3.ªk«ß¨Æ¥ó¤§¬ÛÃö¤å®Ñ®×¸¹:³Ì°ªªk°|¼f²z¤¤(ì¼f®×¸¹:°ªµ¥ªk°|»O«n¤À°|110¦~«× «¤W¦r²Ä76¸¹)4.¨Æ¹êµo¥Í¤é:111/10/245.µo¥Íì©e¡]§tª§³^¼Ðªº¡^:½Ð¨D²×¤îɦWµn°O¤§¥Á¨Æ¶D³^¡Aì§i¹ïì¼f®×¸¹109¦~«× «¶D¦r²Ä139¸¹§P¨M´£¥X¤W¶D¡A»O«n°ªµ¥ªk°|110¦~«× «¤W¦r²Ä76¸¹©ó111/08/31»é¦^¤W¶D¡A©ó¤µ¤é¦¬¨ìì§i¤£ ªA§P¨M¤§¤W¶Dª¬¡C6.³B²z¹Lµ{:«Ý³Ì°ªªk°|½T©w¦¬®×¤Î¤À®×«á¡A±N©e¥Ñ«ß®v³B²z¡C7.¹ï¤½¥q°]°È·~°È¼vÅT¤Î¹w¦ô¼vÅTª÷ÃB:¹ï¥»¤½¥q°]°È·~°ÈµL«¤j¼vÅT¡C8.¦]À³±¹¬I¤Î§ïµ½±¡§Î:«Ý¦¬¨ì¬ÛÃö¤å®Ñ«á¡A¦p»Ý¶i¤@¨B¸É¥R»¡©ú¡A±N¥t¦æ¤½§i¡C9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | ²»Öö»sÃÄ ¿³ | ¤½§i¥»¤½¥q¸³¨ÆÃã¥ô |
1.µo¥ÍÅܰʤé´Á:111/10/242.¿ï¥ô©ÎÅܰʤHû§O¡]½Ð¿é¤Jªk¤H¸³¨Æ¡Bªk¤HºÊ¹î¤H¡B¿W¥ß¸³¨Æ¡B¦ÛµM¤H¸³¨Æ©Î¦ÛµM¤HºÊ¹î¤H¡^:¦ÛµM¤H¸³¨Æ3.ÂÂ¥ôªÌ¾ºÙ¤Î©m¦W:¶Àª÷¹©4.ÂÂ¥ôªÌ²¾ú:¥»¤½¥q¸³¨Æ5.·s¥ôªÌ¾ºÙ¤Î©m¦W:¤£¾A¥Î6.·s¥ôªÌ²¾ú:¤£¾A¥Î7.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¸Ñ¥ô¡v¡B¡u¥ô´Á©¡º¡¡v¡B¡u³u¥@¡v©Î¡u·s¥ô¡v¡^:Ãã¾8.²§°Êì¦]:Ó¤H¦]¯À9.·s¥ôªÌ¿ï¥ô®É«ùªÑ¼Æ:¤£¾A¥Î10.ì¥ô´Á¡]¨Òxx/xx/xx ~ xx/xx/xx¡^:110/07/09¦Ü113/07/0811.·s¥ô¥Í®Ä¤é´Á:¤£¾A¥Î12.¦P¥ô´Á¸³¨ÆÅܰʤñ²v:1/613.¦P¥ô´Á¿W¥ß¸³¨ÆÅܰʤñ²v:¤£¾A¥Î14.¦P¥ô´ÁºÊ¹î¤HÅܰʤñ²v:¤£¾A¥Î15.ÄݤT¤À¤§¤@¥H¤W¸³¨Æµo¥ÍÅÜ°Ê¡]½Ð¿é¤J¬O©Î§_¡^:§_16.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¤½¥q©ó111¦~10¤ë24¤é±µÀòÃã¥ô®Ñ¡A¨Ã©ó111¦~10¤ë25¤é°_¥Í®Ä<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | ÷~°¥¬ì§Þ ¿³ | ¤½§i111¦~09¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê¤ñ²v ¤Î |
¤½§i111¦~09¤ë¥÷¦Ûµ²¦X¨Ö°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê¤ñ²v ¤Î³t°Ê¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/242.µo¥Í½t¥Ñ:¨ÌÂd¶R¤¤¤ßÃÒÂd¼f¦r²Ä1030101342¸¹¨çn¨D¿ì²z¤½§i3.°]°È¸ê°T¦~«×¤ë¥÷:111¦~09¤ë4.¦Ûµ²¬y°Ê¤ñ²v:111.49%5.¦Ûµ²³t°Ê¤ñ²v:73.32%6.¦Ûµ²t¶Å¤ñ²v:63.67%7.¦]À³±¹¬I:¨C¤ë©³«e¤½§i¦Ûµ²¦X¨Ö°]°È³ø§iºI¦Ü«e¤@¤ë©³¤§t¶Å¤ñ²v¡B¬y°Ê¤ñ²v¤Î³t°Ê¤ñ²v8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | °®ªM ¿³ | ¤½§i¥»¤½¥q111¦~9¤ë¥÷°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê¤ñ²v¤Î³t°Ê¤ñ |
¤½§i¥»¤½¥q111¦~9¤ë¥÷°]°È³ø§i¤§t¶Å¤ñ²v¡B¬y°Ê¤ñ²v¤Î³t°Ê¤ñ²v 1.¨Æ¹êµo¥Í¤é:111/10/242.µo¥Í½t¥Ñ:¨Ì¾Ú°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß111¦~9¤ë19¤éÃÒÂd¼f¦r ²Ä1110101577¸¹¨ç³W©w¿ì²z¡C3.°]°È¸ê°T¦~«×¤ë¥÷:111¦~9¤ë4.¦Ûµ²¬y°Ê¤ñ²v:112.13%5.¦Ûµ²³t°Ê¤ñ²v:83.84%6.¦Ûµ²t¶Å¤ñ²v:66.43%7.¦]À³±¹¬I:©ó¨C¤ë©³«e¤½§i¥Ó³ø¦Ûµ²¦X¨Ö°]°È³ø§iºI¦Ü«e¤@¤ë©³¤§t¶Å¤ñ²v¡B ¬y°Ê¤ñ²v¤Î³t°Ê¤ñ²v¡C8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/24 | ¥þºÖ¥Íª« ¿³ | ¤½§i¥»¤½¥q±µÀò¬ü°êFDA End-of-Phase 2 (E |
¤½§i¥»¤½¥q±µÀò¬ü°êFDA End-of-Phase 2 (EOP2)·|«e·N¨£ 1.¨Æ¹êµo¥Í¤é:111/10/212.¤½¥q¦WºÙ:¥þºÖ¥Íª«¬ì§ÞªÑ¥÷¦³¤½¥q3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î5.µo¥Í½t¥Ñ: ¥»¤½¥q¥Î©óªvÀø°®²´¯gªº¶}µo¤¤·sÃÄBRM421¡A¤é«e¦V¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)´£¥X¤G ´ÁÁ{§É¸ÕÅç«áEnd-of-Phase 2 (EOP2)¿Ô¸ß·|ij¥Ó½Ð¡A¨Ã¦w±Æ©ó111¦~10¤ë24¤é»P¬ü°ê FDA¶i¦æEOP2·|ij¡A¥B©ó111¦~10¤ë21¤é±µÀò¬ü°êFDA·|«e·N¨£¡C6.¦]À³±¹¬I: ¬ü°êFDA©ó·|«e·N¨£¤¤¦P·N¥»¤½¥q¤T´ÁÁ{§É¸ÕÅç³Wµe¡A¨Ãµ¹¤©¥¼¨Ó¥Ó½ÐÃÄÃÒ(NDA)©Ò»Ý¸ê ®Æ¤§«Øij¡A¨ú®øìq©ó111¦~10¤ë24¤éEOP2·|ij¡A¥»¤½¥q±N¨Ì»¼¥æ¬ü°êFDA¤§¤T´ÁÁ{§É¸Õ Åçpµe¡A¥Ó½Ð°õ¦æ¬ü°ê¤T´ÁÁ{§É¸ÕÅç¡C7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (¤@)¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GBRM421 (¤G)¥Î³~¡GBRM421¥Î©óªvÀø°®²´¯g¯e¯f¡C (¤T)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤T´ÁÁ{§É¸ÕÅç¡C (¥|)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (1)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã/¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG/µo¥Í¨ä ¥L¼vÅT·sÃĬãµo¤§«¤j¨Æ¥ó¡G´£¥X¥Ó½Ð¬ü°ê¤T´ÁÁ{§É¸ÕÅç¡A¨Ã¿n·¥´M§ä±ÂÅv¦X §@¹ï¶H¡C (2)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¥¼¹F²Îp ¤WÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§«¤j¨Æ¥óªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³ ±¹¬I¡G¤£¾A¥Î¡C (3)¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¹F²Îp¤W ÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¥»¤½¥q«áÄò ±N³W¹º¥Ó½Ð°õ¦æ¬ü°ê¤T´ÁÁ{§É¸ÕÅç¡A¨Ã¿n·¥´M§ä±ÂÅv¦X§@¹ï¶H¡C (4)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦]À³¥¼¨Ó°ê»Ú±ÂÅv½Í§Pµ¦²¤¤Î«O»Ù§ë¸ê¤HÅv¯q¡A¬G¤£ ¤©´¦ÅS¡C(¤)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G (1)¹wp§¹¦¨®É¶¡¡G±N¶i¤J¤T´ÁÁ{§É¸ÕÅç¡A±©¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×½Õ¾ã¡C (2)¹wpÀ³t¾á¤§¸q°È¡G¤£¾A¥Î¡C(¤»)É]³õ²{ªp¡G ÀH¥þ²y°ªÄ֤ƤH¤f«ùÄò¤W¤É¡A°ªÄ֤ƤH¤f¦¨ªø¤]³y¦¨¦]¦Ñ¤Æ¬ÛÃö¯e¯fªº´NÂå¤H¤f¤W ¤É¡A¨ä¤¤²´¬ì¯e¯f§Y¬°¦Ñ¤Æ«áªº«n¯e¯f¤§¤@¡C®Ú¾Ú Prevent Blindness ²Îp¡A ¬ü°êªá¶O¦b²´·ú¯e¯f¤WªºÂåÀø¤ä¥X¥e©Ò¦³ºC©Ê¯f¤ä¥Xªº12%¡C¨ä¤¤ªñµø¨¾ªv¡B²´©³ ¦å²´¯fÃĪ«¡B°®²´¯gÃĪ«µ¥±N¦¨¬°²´¬ì³Ì¨ã¼Wªø¼ç¤Oªº²Ó¤À»â°ì¡C°®²´¯g¬O±`¨£²´ ¬ì¯e¯f¤§¤@¡Aªñ¦~¨Ó¦]ªø®É¶¡±µÄ²3C²£«~¡BÁô§Î²´Ãè¨Ï¥Î¼W¥[¤Îªñµø¹p®g¤â³N¡A¾É P°®²´¯g¤H¤f«æ³t¤W¤É¡A±q«e¦nµo©ó¦Ñ¦~¤H¡A²{¤µ¦~ÄÖ¼h¤U°¬Ò¦³¦¹¯gª¬°ÝÃD¡C®Ú ¾ÚGlobaData¡mDryEyeSyndrome: Global Drug Forecast and Market Analysis to 2028¡n¸ê®ÆÅã¥Ü¡A¥þ²yÃÄ«~¥Dn¥«³õ¥Dn¬°¬ü°ê¡B¼Ú¬w¤Î¨È¤Óµ¥¦a°Ï¡C107¦~°®²´¯g ªº¥þ²y¥Dn¥«³õ¬°39»õ¬ü¤¸¡A117¦~±N¹F110»õ¬ü¤¸¡A107¦~~117¦~§¡½Æ¦X¼Wªø²v (CGAR)¬°10.6%¡C ¥Ø«e¤wÀò¬ü°êFDA®Ö¥i¤WÉ]¤§°®²´¯gÃĪ«¦³¡GRestasis (Allergan)¡BXiidra (Novartis)¡BEysuvis (Kala)¤ÎTyrvaya (Oyster Point)¡C¨ä¤¤Restasis»PXiidra §@¥Î¾÷Âà¬Û¦ü¡A¥i§í¨î°®²´ªºµoª¢¤ÏÀ³»P¨ë¿E²\²G²£¥Í¡A±©ÃÄ»ù©ù¶Q¡B¦ñÀH¸û°ª¤ñ ¨Ò¤§¨`¼ö·P¡CEysuvis¬°¥Ö½èÃþ©T¾JÃĪ«¡A¶È³Q¬ü°êFDA§åã¥Î©óµu´Á(³Ì¦h¨â¶g)ªv Àø¡AµLªkªø´Á¨Ï¥Î¡CTyrvaya¬°»ó¼Q¾¯¡A¥D¦¨¥÷¬°¦ÑÃÄ·s¥Î¡A¹L©¹¥Î©ó»²§U§ÙµÒ±M¥Î ªº¤fªAÃĪ«Chantix¡A¨ä¥Dn¬°³z¹L»ó¼Q¾¯¤è¦¡¡A¨ë¿E²\²G²£¥Í¡C(¤C)·sÃĶ}µo®Éµ{ªø¡A§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë ¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
2022/10/23 | µØ¼w°Ê¯à ¿³ | °w¹ï²H¤ô«È¹B¤TªÛ¯¸µo¥Í¹q°Ê¤j¤Ú(¨®¸¹:EAL-0057)©ó¤µ |
°w¹ï²H¤ô«È¹B¤TªÛ¯¸µo¥Í¹q°Ê¤j¤Ú(¨®¸¹:EAL-0057)©ó¤µ¤é ¤U¤È§¹¦¨¥R¹q«á±Ò°Ê¥D¹q¤O¹q·½µo¥Í°_¤õ¿U¿N¨Æ¥ó»¡©ú 1.¨Æ¹êµo¥Í¤é:111/10/232.¤½¥q¦WºÙ:µØ¼w°Ê¯à¬ì§ÞªÑ¥÷¦³¤½¥q3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î5.µo¥Í½t¥Ñ:°w¹ï²H¤ô«È¹B¤TªÛ¯¸µo¥Í¹q°Ê¤j¤Ú(¨®¸¹:EAL-0057)©ó¤µ¤é¤U¤È§¹¦¨¥R¹q«á±Ò°Ê¥D¹q¤O¹q·½µo¥Í°_¤õ¿U¿N¨Æ¥ó»¡©ú6.¦]À³±¹¬I:¤@¡B¤µ¤é¤U¤È¤GÂI¥ª¥k¡A²H¤ô«È¹B¤TªÛ¯¸µo¥Í¥»¤½¥qªº©³½L¦b¤G¦~«e©e°Uª÷Às¨T¨®»s³y(ªÑ)¤½¥q¥´³yªº¹q°Ê¤j¤Ú(¨®¸¹:EAL-0057)¡A¦b§¹¦¨¥R¹q«á±Ò°Ê¥D¹q¤O¹q·½µo¥Í°_¤õ¿U¿N¨Æ¥ó¡A¨Ãªi¤Î®ÇÃ䨮½ø(¨®¸¹:EAL-0052)¡A³y¦¨¤G½ø¹q°Ê¤j¤Ú¿N·´¡C¤G¡B¦¹¨®½ø¤§¹q¦À¬°¤é¥»»s³y¨S¦³¥ô¦ó¨Æ¬G°O¿ý¡A¹q¦À½c¤Î¨t²Î¥ç¨ú±o¼Ú¬w¦w¥þªk³WECE-R100-2¤§¦w¥þ»{ÃÒ¡AY¦³¥ô¦ó²§±`¬Ò¦³«OÅ@¾÷¨î¡C¤T¡B¦¹¨®½ø°_¤õì¦]¡A¥»¤½¥q§Þ³N¹Î¶¤³¦P¤õ¨aŲ©w¤HûÁA¸Ñ¤¤¡A«Ý§P©w¬O¨®½ø©Î¤H¬°²¨¥¢³y¦¨¡C¥|¡B¥»¤½¥q¥X¼t¤§²£«~§¡§ë«O²£«~³d¥ôÀI¡A¦¹¦¸²H¤ô«È¹B¤TªÛ¯¸µo¥Í¹q°Ê¤j¤Ú§¹¦¨¥R¹q«á±Ò°Ê¥D¹q¤O¹q·½µo¥Í°_¤õ¿U¿N¨Æ¥ó¡A¹ï¥»¤½¥q¨ÃµL«¤j°]°È¼vÅT¡C7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸> |
|
|